3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Completed
3
Recruiting
2
No longer available
1
Sponsor Class
OTHER
8
INDUSTRY
2
NIH
1
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Interventions
pembrolizumab
241
Carboplatin
167
Injections
138
Paclitaxel
119
Gemcitabine
116
Bevacizumab
112
Cisplatin
105
Docetaxel
82
Cyclophosphamide
78
Pemetrexed
76
Capecitabine
69
Fluorouracil
67
Oxaliplatin
65
Fulvestrant
57
fludarabine
55
Nivolumab
55
Leucovorin
52
Cetuximab
52
130-nm albumin-bound paclitaxel
47
Dexamethasone
46
Rituximab
41
atezolizumab
37
venetoclax
35
Drug Therapy
35
toripalimab
34
enzalutamide
34
Irinotecan
34
durvalumab
32
Prednisone
32
Letrozole
32
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
INDUSTRY
×
revumenib
×
Clear all
NCT07211958
2026-05-20
REVEAL-ND NPM1
Syndax Pharmaceuticals
Phase 3
Recruiting
468 enrolled
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA